Adhera Therapeutics Announces Appointed Zahed Subhan PhD MBA JD As CEO, Senior Management Changes, Plans For NASDAQ Uplist
Adhera Therapeutics Announces Appointed Zahed Subhan PhD MBA JD As CEO, Senior Management Changes, Plans For NASDAQ Uplist
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB:ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company's Board of Directors (the "Board") appointed Zahed Subhan PhD MBA JD as Chief Executive Officer of Adhera Therapeutics, effective September 30, 2022. The same day, Dr. Subhan was elected to serve as Chairman of the Board.
巴吞魯日，洛杉磯，9月2022年9月19日(Global Newswire)--臨牀階段生物製藥公司Adhera治療公司(場外交易代碼：ATRX)(“Adhera”或“公司”)今天宣佈，公司董事會(“董事會”)於2022年9月8日任命Zahed Subhan博士MBA JD為Adhera治療公司的首席執行官，自2022年9月30日起生效。同一天，蘇班博士被選為理事會主席。
Dr. Subhan has been serving as a Company Director since November 5, 2021, and has more than 35 years' experience in research, development and commercialization in multinational pharmaceutical companies, including Sanofi, GlaxoSmithKline, Dupont Pharmaceuticals, and as Senior Management/CEO of both public and privately held biotechnology companies.
Subhan博士自2021年11月5日以來一直在董事公司任職，在跨國製藥公司(包括賽諾菲、葛蘭素史克、杜邦製藥)的研發和商業化方面擁有超過35年的經驗，並曾擔任上市和非上市生物技術公司的高級管理/首席執行官。
"We are pleased to be in the final stages of an important but necessary transition from a service-led business model to that of a clinical stage biopharmaceutical company that has the potential to build real value for shareholders. In that regard, we are committed to uplist to a national exchange and accelerating the development of our pipeline addressing truly unmet medical needs in Parkinson's disease and Type 1 diabetes," commented Dr. Subhan.
蘇伯漢博士評論説：“我們很高興處於從以服務為主導的商業模式向有潛力為股東創造真正價值的臨牀階段生物製藥公司的重要但必要的過渡的最後階段。在這方面，我們致力於提升到一個全國性的交易所，並加快我們的管道的發展，以滿足帕金森氏病和1型糖尿病真正未得到滿足的醫療需求。”
Andrew "Al" Kucharchuk, the current Chief Executive Officer, will continue to hold the position until September 30, 2022, at which time he will assume the Company's new position of Chief Operating Officer at Adhera with responsibilities for the daily operations of the company, including the CFO function, Corporate Development and Investor Relations. Al will also be seated as Vice-Chairman of the Board.
現任首席執行官安德魯·庫哈爾丘克將繼續擔任這一職位，直到2022年9月30日，屆時他將擔任公司在Adhera的首席運營官，負責公司的日常運營，包括首席財務官職能、公司發展和投資者關係。Al還將擔任董事會副主席。
"I want to thank Al for his expert stewardship of Adhera during a particularly challenging time. We have Al to thank for many of our accomplishments, including the in-licensing of our phase 2 ready drug candidates, thus spearheading Adhera's transition to a biopharmaceutical company. Looking forward, it was pertinent to re-align the leadership team in the most prudent manner to achieve our next major milestones, including filing a Form S-1 with the Securities and Exchange Commission and initiating phase 2 clinical trials of MLR-1019 and MLR-1023. I look forward to serving as CEO and Chairman and welcome a steady and transparent line of communication with our shareholders."
我要感謝Al在一個特別具有挑戰性的時期對Adhera的專家管理。我們要感謝Al為我們取得的許多成就，包括我們的第二階段準備好的候選藥物獲得許可，從而引領Adhera向一家生物製藥公司轉型。展望未來，以最謹慎的方式重新調整領導團隊，以實現我們下一個主要里程碑，包括向證券交易委員會提交S-1表格，以及啟動MLR-1019和MLR-1023的第二階段臨牀試驗。我期待着擔任首席執行官和董事長，並歡迎與我們的股東建立穩定和透明的溝通渠道。
Separately, the Company wishes to inform shareholders that a new corporate website has been designed and is being completed that best reflects the portfolio and mission of Adhera Therapeutics today. There will be a short period of downtime while the old website is removed and new website is installed, tested, and brought live.
另外，公司希望告知股東，一個新的公司網站已經設計並正在完成，最能反映Adhera Treateutics目前的投資組合和使命。在刪除舊網站並安裝、測試和啟用新網站期間，將有一段短時間的停機時間。
譯文內容由第三人軟體翻譯。